多发性骨髓瘤诊治过程中血清脂联素、瘦素和抵抗素的变化研究

目的 研究多发性骨髓瘤(MM)初诊和化疗过程中血清脂联素、瘦素和抵抗素水平的变化.方法 选择接受相同的化疗方案的MM患者30例和健康成年人50例,测定治疗过程中血清中的脂联素、瘦索和抵抗索水平的变化,同时测定血清中的乳酸脱氢酶(LDH)浓度.结果 初诊时患者血清中的脂联素和抵抗素水平明最低于正常对照组,而瘦索表达明显升高.经过化疗后,MM患者血清中的脂联索水平呈现明显上升的趋势.相关性分析显示治疗过程中的脂联素与LDH呈现明显的负相关,而瘦素与LDH呈现明显的正相关.结论 多发性骨髓瘤初诊时血清中的脂联素和抵抗素水平明显降低,瘦素水平明显升高,并且脂联素水平随着MM治疗的进展逐渐趋于正常.     

血清脂联素、瘦素和抵抗素与急性淋巴细胞性白血病的相关性研究

目的 研究急性淋巴细胞性白血病(ALL)初诊和化疗过程中血清脂联素、瘦素和抵抗素水平的变化.方法 选择接受相同的化疗方案的ALL患者,其中成人30例,儿童45例,用双抗体夹心ABC-ELISA法测定治疗过程中血清中的的脂联素、瘦素和抵抗素水平的变化,同时测定血清中的乳酸脱氢酶浓度.结果 与正常对照组相比,成人初诊时血清中的脂联素水平明显降低,而瘦素水平明显升高,前者经过化疗后呈现明显上升趋势,并与LDH明显的负相关.儿童脂联素水平呈现与成人相同的变化,不过初诊时的瘦素和抵抗素水平均升高,瘦素水平经过化疗后出现明显的下降趋势,并且与LDH呈显著的正相关.结论 急性淋巴细胞性白血病初诊时血清中的脂肪素水平出现显著变化,而且会随着ALL治疗的进展逐渐趋于正常.     

单纯性肥胖患者血清脂联素、血清瘦素与肾损伤的相关性分析

目的:研究单纯性肥胖患者血清脂联素、血清瘦素与尿白蛋白、肾小球滤过率相关性及两种脂肪因子对肾脏的作用。方法:选取单纯肥胖患者（肥胖组）60例;同期健康人（对照组）40例,测定两组人群血清脂联素、血清瘦素、身高、体质量、肾功能及尿白蛋白等,计算两组人群瘦素与脂联素比值、体质量指数（BMI）及肾小球滤过率（GFR）。结果:肥胖组血清脂联素明显低于对照组（P<0.001）;肥胖组血清瘦素明显高于对照组（P<0.001）;肥胖组较对照组尿白蛋白差异明显（P=0.004）;肥胖组血清瘦素/脂联素与对照组差异明显（P<0.001）;脂联素与BMI、尿白蛋白为负相关（r分别为:-0.421、-0.245;P分别为<0.001、0.029）;血清瘦素与BMI正相关(r=0.650,P<0.001),与GFR负相关（r=-0.227,P=0.043）;瘦素/脂联素与BMI正相关（r=0.511,P<0.001）;GFR与BMI正相关（r=0.376,P=0.001）;瘦素、瘦素/脂联素、BMI与尿白蛋白无相关性;脂联素、瘦素/脂联素与GFR无相关性。结论:单纯性肥胖患者血清脂联素水平下降,血清瘦素、尿白蛋白水平升高。瘦素/脂联素比值可能是单纯性肥胖患者肾损伤预后的预测因子。     

2型糖尿病患者血清抵抗素、瘦素、脂联素水平与微血管病变的关系

目的 探讨2型糖尿病患者血清抵抗素、瘦素、脂联素水平与微血管病变的关系.方法 选择河北北方学院附属第一医院2型糖尿病患者(T2DM) 120例,根据是否伴微血管病变,分为无微血管病变组(NON-MAP) 60例和微血管病变组(MAP)60例,另选取健康体检人群(NC)60例,采取酶联免疫吸附试验(ELISA)测定各组空腹抵抗素、瘦素、脂联素水平,并测定各组的空腹血糖、胰岛素和血脂水平,用胰岛素抵抗指数(HOMA-IR)评价胰岛素抵抗.结果 MVP组及NON-MVP组患者血清抵抗素、瘦素、游离脂肪酸(FFA)及超敏C反应蛋白(hs-CRP)水平均显著高于NC组,而脂联素明显低于NC组,差异有统计学意义(P＜0.05);相关分析表明T2DM患者血清抵抗素、瘦素水平与hs-CRP、淳离脂肪酸(FFA)、HOMA-IR、三酰甘油(TG)呈正相关(P＜0.05),与高密度脂蛋白胆固醇(HDL-C)呈负相关(P＜0.05);脂联素水平与hs-CRP、FFA、HOMA-IR、TG呈负相关,与HDL-C呈正相关(P＜0.05);血清抵抗素、瘦素水平呈明显正相关,而二者与脂联素均呈明显负相关;以血清抵抗素、瘦素、脂联素为因变量,进行多元线性逐步回归分析显示,对三者影响最大的是HOMA-IR和腰臀比(WHR).结论 T2DM患者血清抵抗素、瘦素水平升高、脂联素水平降低,提示血清抵抗素、瘦素、脂联素水平与T2DM的发病及其微血管病变的发生相关.     

抵抗素和脂联素与妊娠期高血压疾病的相关性研究

目的探讨抵抗素和脂联素与妊娠期高血压疾病(HDCP)的关系及其在发病过程中的作用。方法以100例妊娠期高血压疾病孕妇为观察组,其中轻度子痫前期69例,重度子痫前期31例;选取同期100例正常孕晚期孕妇为对照组。采用酶联免疫吸附法(ELISA法)检测孕妇血清抵抗素和脂联素水平,同时检测空腹血糖(FBG)水平、空腹胰岛素(FINS)水平,计算胰岛素抵抗指数(IRI)。结果随病情进展血清脂联素水平逐渐下降,而抵抗素水平逐渐升高,差异有统计学意义(P<0.01)。轻度、重度子痫前期患者血清抵抗素水平与胰岛素抵抗指数呈现显著正相关(r=0.805、r=0.819,P<0.01),脂联素水平与胰岛素抵抗指数呈现显著负相关(r=-0.784、r=-0.795,P<0.01),抵抗素与脂联素水平呈现显著负相关(r=-0.845、r=-0.858,P<0.01)。结论抵抗素和脂联素在HDCP的发病过程中起着相反的作用,抵抗素的致病作用和脂联素保护作用可能是通过改变胰岛素抵抗实现的,二者有望成为临床预测HDCP发病及严重程度的指标。     

2型糖尿病患者血清抵抗素、瘦素、脂联素水平与外周动脉弹性及舒张功能的相关性研究

目的 探讨2型糖尿病患者血清抵抗素、瘦素、脂联素水平与颈动脉弹性指标及肱动脉血管舒张功能的相关性.方法 选取2014年12月至2015年8月收治的2型糖尿病(T2DM)患者60例(T2DM组)、糖耐量异常(IGT)患者50例(IGT组)和体检健康者50例(NC组),采用酶联免疫吸附试验(ELISA)检测其血清抵抗素、瘦素、脂联素水平;同时应用回声跟踪技术(ET)检测颈动脉压力应变弹性系数(Ep)、动脉顺应性(AC)、硬化参数(β)、脉搏波传导速度(PWVβ)、管径增大指数(AI);并测量肱动脉内径变化率,变化率小于4％定义为非内皮依赖性血管舒张功能(EID)受损.结果 NC组、IGT组、T2DM组血清抵抗素、瘦素水平、Ep、β、AI、PWVβ值及EID受损率依次增高,脂联素水平及AC则逐步降低,各组间比较差异均有统计学意义(P＜0.01);T2DM患者血清抵抗素、瘦素水平与β、PWVβ及EID受损率呈正相关,而脂联素水平则与β、PWVβ及EID受损率呈负相关(P＜o.05);T2DM患者血清抵抗素、瘦素水平均与脂联素呈负相关(均P=0.ooo).结论 T2DM患者血清抵抗素、瘦素、脂联素水平与颈动脉β、PWVβ、EID受损有明显相关性,三者均是早期发现外周动脉弹性和舒张功能病变的敏感指标.     

脂肪细胞因子与肥胖的关系

目的:研究脂肪细胞因子chemerin?血清瘦素?抵抗素?脂联素水平及其相互关系,探讨肥胖的发生发展机制?方法:通过体格测量测定正常对照组和肥胖组的腰围?臀围;另通过生化法检测瘦素?抵抗素?脂联素?chemerin的水平?空腹血糖(FBS)?胆固醇(TC)?甘油三酯(TG)?低密度脂蛋白胆固醇(LDL-C)?高密度脂蛋白胆固醇(HDL-C)?空腹胰岛素(FINS),同时计算胰岛素抵抗指数(HOMA-IR)?结果:①肥胖组血清抵抗素?瘦素及chemerin水平高于正常对照组,而脂联素水平明显降低(P < 0.05);②相关性分析显示血清抵抗素?chemerin与脂联素呈负相关而与腰围?腰臀比?瘦素呈正相关?结论:肥胖患者抵抗素及瘦素?chemerin明显升高,而脂联素降低,其表达水平与肥胖类型(尤其中心性肥胖)及程度密切相关?     

瘦素及脂联素在子痫前期患者血清中的表达及相关性研究

目的 检测子痫前期患者血清瘦素及脂联素的表达并探讨瘦素与脂联素的相关性.方法 采用酶联免疫吸附法检测44例子痫前期患者及24例正常孕妇血清中瘦素、脂联素的表达水平.结果 ①轻、重度子痫前期组血清瘦素水平明显高于正常对照组,差异分别有显著性和极显著性意义(P＜0.05,P＜0.01);②轻、重度子痫前期组血清脂联素水平明显低于正常对照组,重度组与对照组之间的差异有显著意义(P＜0.05);③重度组中瘦素与脂联素呈低度负相关(r=-0.342;P＜0.05 ).结论 瘦素、脂联素参与了子痫前期的发病.     

高血压患者血清抵抗素和血脂的相关研究

目的 探讨高血压患者血清抵抗素水平与血压、瘦素、脂联素等之间的关系.方法 60例高血压患者和65例健康对照组,都按照体重指数分为两个亚组,常规测量血压、体重、身高,计算体重指数,抽取空腹静脉血检测其血糖、血脂、空腹胰岛素、瘦素、脂联素和抵抗素.结果 高血压患者与健康对照组比较,抵抗素水平显著升高[(22.35±2.05)μg/L比(25.15±1.77)μg/L,P＜0.01],将高血压两亚组合并后,抵抗素与低密度脂蛋白(γ=0.599)和胰岛素(γ=0.640)呈正相关,与脂联素(γ=0.711)呈负相关;多元线性回归提示,低密度脂蛋白(B=1.258)、胰岛素(B=0.785)和脂联素(B=-0.215)共同影响着抵抗素水平.结论 在高血压患者中,抵抗素水平升高与血压之间有一定的相关性,其机制可能是通过低密度脂蛋白和脂联素而实现的.     

结肠癌患者脂肪因子检测的临床意义

目的探讨结肠癌患者血清脂肪因子水平变化的临床意义。方法选择结肠癌患者96例(结肠癌组),其中Dukes病理临床分期A期26例,B期20例,C期28例,D期22例。选择同期健康体检的30例健康成人作为对照组。采用免疫酶联吸附法(ELISA)法检测血清脂联素、内脂素、抵抗素、瘦素水平。分析结肠癌患者血清脂肪因子的变化以及与Dukes病理分期的关系、不同浓度脂肪因子的结肠癌患者3年生存率的差别。结果与对照组比较,结肠癌患者血清抵抗素、内脂素和瘦素水平升高,脂联素水平降低(均P<0.05)。与Dukes分期A—B期患者比较,C—D期患者血清抵抗素、内脂素和瘦素水平明显升高,脂联素水平明显下降(均P<0.05)。低质量浓度和高质量浓度内脂素结肠癌患者3年累积生存率分别为80.52%和65.30%(P=0.044);低质量浓度和高质量浓度瘦素结肠癌患者3年累积生存率分别为82.60%和64.30%(P=0.049);低质量浓度和高质量浓度抵抗素结肠癌患者3年累积生存率分别为80.43%和60.00%(P=0.043 6);低质量浓度和高质量浓度脂联素结肠癌患者3年累积生存率分别为60.20%和80.50%(P=0.026 6)。结论血清脂肪因子的检测对结肠癌患者具有病情判断和预后评估的价值。 更多     

Adipocytokines and breast cancer risk

Background Many researches suggested that obesity increased the risk of breast cancer, but the mechanism was currently unknown. Adipocytokines might mediate the relationship. Our study was aimed to investigate the relationship between serum levels of resistin, adiponectin and leptin and the onset, invasion and metastasis of breast cancer. Methods Blood samples were collected from 80 newly diagnosed, histologically confirmed breast cancer patients and 50 age-matched healthy controls. Serum levels of resistin, adiponectin and leptin were determined by enzyme-linked immunosorbent assays (ELISA); fasting blood glucose (FBG), lipids, body mass index (BMI), and waist circumference (WC) were assayed simultaneously.Results Serum levels of adiponectin ((8.60±2.92) mg/L vs (10.37±2.81) mg/L, P=0.001) and HDL-c were significantly decreased in breast cancer patients in comparison to controls. Serum levels of resistin ((26.35±5.36) μg/L vs (23.32±4.75) μg/L, P=0.000), leptin ((1.35±0.42) μg/L vs (1.06±0.39) μg/L, P=0.003), FBG and triglyceride (TG) in breast cancer patients were increased in contrast to controls, respectively. However, we did not find the significant difference of the serum levels of resistin, adiponectin and leptin between premenopausal breast cancer patients and healthy controls (P＝0.091, 0.109 and 0.084, respectively). The serum levels of resistin, adiponectin and leptin were significantly different between patients with lymph node metastasis (LNM) and those without LNM (P=0.001, 0.000 and 0.006, respectively). The stepwise regression analysis indicated that the tumor size had the close correlation with leptin (R(2)=0.414, P=0.000) and FBG (R(2)=0.602, P=0.000). Logistic regression analysis showed that reduced serum levels of adiponectin (OR: 0.805; 95%CI: 0.704–0.921; P＝0.001), HDL (OR: 0.087; 95%CI: 0.011–0.691, P＝0.021), elevated leptin (OR: 2.235; 95%CI:1.898–4.526; P＝0.004) and resistin (OR: 1.335; 95%CI: 1.114–2.354; P＝0.012) increased the risk for breast cancer; Reduced serum levels of adiponectin (OR: 0.742; 95%CI: 0.504–0.921; P=0.003) and elevated leptin (OR: 2.134; 95%CI:1.725–3.921; P= 0.001) were associated with lymph node metastasis of breast cancer. Conclusions The decreased serum adiponectin levels and increased serum resistin and leptin levels are risk factors of breast cancer. The low serum adiponectin levels and high serum leptin levels are independent risk factors for metastasis of cancer. The association between obesity and breast cancer risk might be explained by adipocytokines.     

Association between four adipokines and insulin sensitivity in patients with obesity, type 1 or type 2 diabetes mellitus, and in the general Chinese population

Background Hyperinsulinemic euglycemic clamp is the gold standard to evaluate the insulin sensitity, but it is too complicated and expensive to use in clinic.We tried to find an alternative indicator to reflect insulin sensitivity.To evaluate the association between the four adipokines, adiponectin, leptin, resistin and tumor necrosis factor-α （TNF-α） with insulin sensitivity, we used a hyperinsulinemic euglycemic clamp to test insulin sensitivity in Chinese patients with obesity and type 1 or type 2 diabetes mellitus versus controls.Methods In this parallel control study, we tested insulin sensitivity using a hyperinsulinemic euglycemic clamp in different groups, then examined levels of adiponectin, leptin, resistin and TNF-α in serum, and the relationship between the different adipokines and glucose disposal rate （M value）, as well as insulin sensitivity index （M value/insulin, M/I）,which are the ＂gold standard＂ indices of insulin sensitivity.Results There were significant differences in mean leptin values in the four adipokines from the four different groups （P〈0.001; comparison of the variation between different groups was analyzed by variance analysis）.Compared to controls （using multiple comparison two-way Dunnett t test）, only the leptin level showed significant differences in the four adipokines from the four different groups at the same time （P 〈0.001）.The association analysis between the different adipokines and M or M/I values also showed that only leptin negatively correlated with M （r=-0.64, P 〈0.001） or M/I values （r=-0.56, P〈0.001）; there was no relationship between the other three adipokines and M or M/I values.Conclusion Only leptin was associated with M or M/I values.Therefore, leptin might be one of the predictive factors of the degree of insulin resistance and risk of the accompanying disease.     

高血压前期中医辨证分型与脂联素、瘦素、抵抗素水平的相关性研究

[目的] 研究脂联素、瘦素、抵抗素水平对高血压前期及其中医辨证分型的影响,并探讨其水平与年龄、体重指数、收缩压、舒张压、平均动脉压的相关性。[方法] 纳入初诊为高血压前期组受试者79 例,其中肝火亢盛型20 例、阴虚阳亢型18例、痰湿壅盛型22 例、阴阳两虚型19 例,同时纳入理想血压健康体检组受试者15 例为对照组。分别测定上述受试者空腹血清脂联素、瘦素、抵抗素水平,并进行统计分析。[结果] 1)高血压前期组空腹血清脂联素显著低于对照组(P<0.01),空腹血清瘦素、抵抗素水平显著高于对照组(P<0.01)。2)痰湿壅盛型受试者脂联素水平低于其他3 个证型(P<0.05),瘦素、抵抗素水平高于其他3 个证型(P<0.05),肝火亢盛、阴虚阳亢、阴阳两虚3 个证型经两两比较差异无统计学意义(P>0.05)。3)在高血压前期组中,脂联素水平与收缩压和平均动脉压呈负相关,瘦素与收缩压、舒张压和平均动脉压呈正相关,抵抗素与上述指标无相关性。在对照组中瘦素与年龄、收缩压、舒张压和平均动脉压呈正相关,脂联素、抵抗素与上述指标无明显相关性。[结论] 1)高血压前期组较理想血压组脂联素水平下降,并且瘦素、抵抗素水平升高,且与血压水平有不同程度的相关性,说明脂肪组织可能参与了高血压前期的发生。2)痰湿壅盛型受试者脂联素水平低于其他3 个证型,而瘦素、抵抗素水平高于其他3 个证型,说明脂肪组织的内分泌功能可能影响高血压前期的中医辨证分型,或可成为高血压前期中医辨证分型的客观指标之一。3)对脂肪组织内分泌功能的干预或可成为预防高血压前期发生乃至发展为临床高血压的有效途径。     

Serum adiponectin and resistin levels in patients with polycystic ovarian syndrome and their clinical implications

In this study, serum adiponectin and resistin levels were determined in 46 patients with polycystic ovarian syndrome (PCOS), and their correlation with serum sexual hormones and insulin resistance (IR) were examined.The subjects included 26 obese patients with body mass index (BMI)>25 and 20 non-obese patients with BMI≤25, with 25 obese and 25 non-obese healthy volunteers without PCOS serving as controls.Serum adiponectin and resistin levels in all subjects were measured, and endocrinal and metabolic indices were also analysed.Our results showed that the serum adiponectin levels in both obese and non-obese PCOS groups were significantly lower than their controls, while the serum resistin levels in obese and non-obese PCOS group were significantly higher than in their controls (P<0.001).The serum adiponectin level was significantly lower and serum resistin level significantly higher in the non-obese PCOS group as compared with the obese control group (P<0.05).Serum adiponectin level was negatively correlated with FIN, HOMA-IR, LH and LH/FSH (P<0.05), but serum resistin level was positively correlated with FIN, HOMA-IR, LH and LH/FSH (P<0.05).We are led to conclude that PCOS patients have obvious IR, low serum adiponectin and high serum resistin, and adiponectin and resistin might play important roles in the pathogenesis of IR in PCOS patients.     

地特胰岛素联合罗格列酮对2型糖尿病患者体重指数和血清脂肪细胞因子的影响

目的探讨地特胰岛素联合罗格列酮对2型糖尿病患者体重指数和血清脂肪细胞因子的影响。方法选取初诊2型糖尿病患者48例,随机分为地特胰岛素组(n=24)和中性鱼精蛋白锌胰岛素(NPH)组(n=24),分别用地特胰岛素和中性鱼精蛋白锌胰岛素联合罗格列酮治疗,疗程12周。比较治疗前后两组体重指数、空腹血糖(FPG)、空腹胰岛素(FINS)、糖化血红蛋白(HbA1c)、瘦素、抵抗素和脂联素水平变化。结果治疗后,地特胰岛素组BMI较治疗前降低,但差异无显著性(P>0.05);NPH组BMI较治疗前显著升高,差异具有显著性(P<0.05)。地特胰岛素组、NPH组FPG、HbA1c、FINS、瘦素和抵抗素水平均较治疗前显著下降(P<0.05),其中地特胰岛素组瘦素和抵抗素下降较NPH组明显,差异具有显著性(P<0.05)。地特胰岛素组、NPH组脂联素水平均较治疗前明显升高,其中地特胰岛素组脂联素水平较NPH组升高明显,差异具有显著性(P<0.05)。结论地特胰岛素联合罗格列酮治疗可以避免罗格列酮增加体重的副作用发生,并能增强罗格列酮降瘦素、抵抗素和升高脂联素的作用。     

Serum Adiponectin and Resistin Levels in Patients with Polycystic Ovarian Syndrome and Their Clinical Implicatlons

In this study, serum adiponectin and resistin levels were determined in 46 patients with polycystic ovarian syndrome (PCOS), and their correlation with serum sexual hormones and insulin resistance (IR) were examined. The subjects included 26 obese patients with body mass index (BMI)＞25 and 20 non-obese patients with BMI≤25, with 25 obese and 25 non-obese healthy volunteers without PCOS serving as controls. Serum adiponectin and resistin levels in all subjects were measured, and endocrinal and metabolic indices were also analysed. Our results showed that the serum adiponectin levels in both obese and non-obese PCOS groups were significantly lower than their controls, while the serum resistin levels in obese and non-obese PCOS group were significantly higher than in their controls (P＜0.001). The serum adiponectin level was significantly lower and serum resistin level significantly higher in the non-obese PCOS group as compared with the obese control group (P＜0.05). Serum adiponectin level was negatively correlated with FIN, HOMA-IR, LH and LH/FSH (P＜0.05), but serum resistin level was positively correlated with FIN, HOMA-IR, LH and LH/FSH (P＜0.05). We are led to conclude that PCOS patients have obvious IR, low serum adiponectin and high serum resistin, and adiponectin and resistin might play important roles in the pathogenesis of IR in PCOS patients.     

Serum resistin and adiponectin concentrations in patients with overweight and obesity

Objective： To explore the serum levels of resistin and adiponectin in patients with overweight and obesity. Methods： Fifty-eight cases with normal weight and 24 patients with overweight and obesity have taken fasting blood samples for measurements of plasma glucose, plasma lipids, insulin, C-peptide, thyroid hormones, C-response protein, interleukin-6, TNF-α, leptin, adiponectin and resistin. Results： The concentrations of resistin in cases with overweight and obesity were significant higher than those in the normal weight cases （16. 01 ± 8. 60 vs 11. 63 ± 9. 05 ng/ml, P = 0. 047）. Pearson relation analysis showed that serum resistin concentrations were positively correlated with age （r= 0. 476, P = 0.019）, but negatively correlated with C-peptide （r=-0.45, P=0. 024）, and adiponectin concentrations were positively correlated with HDL-c （r=0. 463, P=0. 023） and systolic blood pressure （r=0. 409, P=0. 047） in overweight and obesity cases. Conclusion： The concentrations of resistin in cases with over-weight and obesity are higher, and there is no correlation between resistin and blood glucose, blood lipids and insulin, while the serum adiponectin concentrations positively correlated with HDL-c and systolic blood pressure.     

辛伐他汀对急性脑梗死患者血脂、抵抗素、脂联素水平及颈动脉内膜—中层厚度的影响

目的探讨辛伐他汀对急性脑梗死患者血脂、抵抗素、脂联素水平及颈动脉内膜—中层厚度(IMT)的影响。方法将急性脑梗死伴颈动脉硬化患者113例随机分为观察组(56例)和对照组(57例),对照组给予基础治疗,观察组在此基础上加用辛伐他汀40 mg口服,疗程均为3个月。2组于治疗前、治疗后检测血脂、抵抗素、脂联素及颈动脉内膜—中层厚度变化。结果与治疗前比较,2组治疗3个月后总胆醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)、抵抗素水平、脑卒中量表(NIHSS)评分及颈动脉内膜—中层厚度均降低,且观察组较对照组降低更明显(P均<0.05);高密度脂蛋白胆固醇(HDL-C)、脂联素水平均升高,且观察组较对照组升高更明显(P<0.05)。相关性分析表明IMT与TC、TG、LDL-C抵抗素呈正相关(r=0.18、0.24、0.16、0.21,P均<0.05),而与脂联素、HDL-C呈负相关(r=-0.26、-0.23,P均<0.05)。结论他汀类药物治疗能有效降低急性脑梗死患者的血脂及抵抗素水平,有效延缓和逆转动脉粥样硬化斑块,减少急性脑梗死的发生。